Marshall Wace’s Xtant Medical Holdings XTNT Stock Holding History

Marshall Wace’s Portfolio XTNT Stock Details XTNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-47,559	Closed	-$112K	–	3164
2021 Q1	$112K	Buy	+47,559	New	+$102K	﹤0.01%	2350

Other funds holding XTNT

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's XTNT Position: Q2 2021 in Review

Marshall Wace sold out of Xtant Medical Holdings (XTNT) in Q2 2021, closing a stake of 47,559 shares — an estimated $112K sold.

Marshall Wace first reported a position in XTNT in Q1 2021 and held it in 1 quarter. The position peaked at $112K in Q1 2021. 20 funds tracked by Wall St. Rank hold XTNT as of Q2 2021.

Marshall Wace reported no remaining Xtant Medical Holdings position as of Q2 2021 after selling out during the quarter.
Marshall Wace sold 47,559 Xtant Medical Holdings shares in Q2 2021, an estimated $112K.
Marshall Wace first reported a position in Xtant Medical Holdings in Q1 2021 and held it in 1 quarter.
Marshall Wace's Xtant Medical Holdings position peaked at $112K in Q1 2021.
20 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q2 2021.

Based on Marshall Wace's 13F filing for Q2 2021, filed 13 Aug 2021.